Piceatannol for COVID-19

Piceatannol may be beneficial for COVID-19 according to the studies below. COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 12,000+ potential treatments. c19early.org analyzes 220+ treatments. We have not reviewed piceatannol in detail.
Amtaghri et al., Phytomedical compounds as promising therapeutic agents for COVID-19 targeting angiotensin-converting enzyme 2: a review, Journal of Pharmacy and Pharmacology, doi:10.1093/jpp/rgae101
Abstract Aims The aim of the present review was to highlight natural product investigations in silico and in vitro to find plants and chemicals that inhibit or stimulate angiotensin-converting enzyme 2 (ACE-2). Background The global reduction of incidents and fatalities attributable to infections with SARS-CoV-2 is one of the most public health problems. In the absence of specific therapy for coronavirus disease 2019 (COVID-19), phytocompounds generated from plant extracts may be a promising strategy worth further investigation, motivating researchers to evaluate the safety and anti-SARS-CoV-2 effectiveness of these ingredients. Objective To review phytochemicals in silico for anti-SARS-CoV-2 activity and to assess their safety and effectiveness in vitro and in vivo. Methods The present review was conducted using various scientific databases and studies on anti-SARS-CoV-2 phytochemicals were analyzed and summarized. The results obtained from the in silico screening were subjected to extraction, isolation, and purification. The in vitro studies on anti-SarcoV-2 were also included in this review. In addition, the results of this research were interpreted, analyzed, and documented on the basis of the bibliographic information obtained. Results This review discusses recent research on using natural remedies to cure or prevent COVID-19 infection. The literature analysis shows that the various herbal preparations (extracts) and purified compounds can block the replication or entrance of the virus directly to carry out their anti-SARS-CoV-2 effects. It is interesting to note that certain items can prevent SARS-CoV-2 from infecting human cells by blocking the ACE-2 receptor or the serine protease TMPRRS2. Moreover, natural substances have been demonstrated to block proteins involved in the SARS-CoV-2 life cycle, such as papain- or chymotrypsin-like proteases. Conclusion The natural products may have the potential for use singly or in combination as alternative drugs to treat/prevent COVID-19 infection, including blocking or stimulating ACE-2. In addition, their structures may provide indications for the development of anti-SARS-CoV-2 drugs.
Brown et al., High-Throughput Screening for Inhibitors of the SARS-CoV-2 Protease Using a FRET-Biosensor, Molecules, doi:10.3390/molecules25204666
The global SARS-CoV-2 pandemic started late 2019 and currently continues unabated. The lag-time for developing vaccines means it is of paramount importance to be able to quickly develop and repurpose therapeutic drugs. Protein-based biosensors allow screening to be performed using routine molecular laboratory equipment without a need for expensive chemical reagents. Here we present a biosensor for the 3-chymotrypsin-like cysteine protease from SARS-CoV-2, comprising a FRET-capable pair of fluorescent proteins held in proximity by a protease cleavable linker. We demonstrate the utility of this biosensor for inhibitor discovery by screening 1280 compounds from the Library of Pharmaceutically Active Compounds collection. The screening identified 65 inhibitors, with the 20 most active exhibiting sub-micromolar inhibition of 3CLpro in follow-up EC50 assays. The top hits included several compounds not previously identified as 3CLpro inhibitors, in particular five members of a family of aporphine alkaloids that offer promise as new antiviral drug leads.
Masoudi-Sobhanzadeh et al., Structure-based drug repurposing against COVID-19 and emerging infectious diseases: methods, resources and discoveries, Briefings in Bioinformatics, doi:10.1093/bib/bbab113
AbstractTo attain promising pharmacotherapies, researchers have applied drug repurposing (DR) techniques to discover the candidate medicines to combat the coronavirus disease 2019 (COVID-19) outbreak. Although many DR approaches have been introduced for treating different diseases, only structure-based DR (SBDR) methods can be employed as the first therapeutic option against the COVID-19 pandemic because they rely on the rudimentary information about the diseases such as the sequence of the severe acute respiratory syndrome coronavirus 2 genome. Hence, to try out new treatments for the disease, the first attempts have been made based on the SBDR methods which seem to be among the proper choices for discovering the potential medications against the emerging and re-emerging infectious diseases. Given the importance of SBDR approaches, in the present review, well-known SBDR methods are summarized, and their merits are investigated. Then, the databases and software applications, utilized for repurposing the drugs against COVID-19, are introduced. Besides, the identified drugs are categorized based on their targets. Finally, a comparison is made between the SBDR approaches and other DR methods, and some possible future directions are proposed.
Sabarimuthu et al., An In Silico Study of Phytochemicals of Cissus quadrangularis as Resources for Docking With Main Protease of SARS COV‐2 and Comparative Analysis, ChemistrySelect, doi:10.1002/slct.74758
ABSTRACT Investigating structurally varied ethnopharmacological scaffolds is still essential for finding long‐lasting inhibitors against SARS‐CoV‐2, despite a great deal of research on synthetic antivirals. Cissus quadrangularis is a well‐known medicinal succulent that is highly prized for its rich therapeutic profile of secondary metabolites. However, its unique multi‐constituent strategy against the essential viral replication enzyme, the main protease (M pro ), is still unknown. By performing a comparative structural screening of phytoconstituents from C. quadrangularis against the catalytically active dimeric form of SARS‐CoV‐2 M pro via docking and simulation analyses, this study filled this knowledge gap. The M pro dimer of COVID‐19 was significantly inhibited by the top ranked phytochemicals of C. quadrangularis viz. luteolin (−7.7 Kcal/mol), quercetin (−7.3 Kcal/mol), kaempferol (−7.2 Kcal/mol), adrenosterone (−7.8 Kcal/mol), resveratrol (−7.0 Kcal/mol), piceatannol (−6.9 Kcal/mol), etc. which had the binding energies indicating their potential for additional in vitro research. These results elucidated the structural and thermodynamic framework behind C. quadrangularis's predicted target interaction, offering a clear computational rationale for prioritizing its specific flavonoid and stilbene components as candidates lead for mandatory future in vitro validation. The molecular docking of M pro dimer of COVID‐19 was visualized using PyMOL and Ligplot.